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Abstract 
 
 
ABSTRACT 
A prospective observational study for a period of 8 months was carried out in the 
general medicine department of a 750 bedded multispecialty tertiary care teaching 
hospital in order to understand various inducers and inhibitors of CYP3A4 
substrates present in prescription and to follow a mechanism based approach in 
the management of drug-drug interactions.  Hundred Prescriptions with at least 
one CYP3A4 enzyme substrate along with either inducer or inhibitor were 
selected for the study. All the selected prescriptions had at least one CYP3A4 
enzyme substrate along with an inducer or inhibitor. Major diagnosis observed in 
study population were hypertension (21%) followed by diabetes mellitus (14%), 
chronic renal failure (12%), and tuberculosis (9%) Nine hundred and twenty five 
drugs belonging to Eighty eight categories were prescribed in the study subjects. 
Of these, vitamins and minerals (33.63%), antibiotics (12.5%), antihypertensives 
(9.09%), antiulcers (6.81%), antiepileptic (6.81%) and anticoagulants (6.81%) 
were most frequently prescribed. Hundred substrates, 66 inhibitors and  
34 inducers of CYP3A4 were identified during the study period. The substrates 
included clopidogrel (47%), atorvastatin (22%), esomeprazole (13%), omeprazole 
(5%) domperidone (4%), midazolam (3%), phenytoin (2%) and azithromycin 
(2%). The various inhibitors of CYP3A4 recorded during the study were 
atorvastatin (45.45%), amlodipine (19.69%), esomeprazole (12.12%), amiodarone 
(7.57%), flucanazole (6.06%), cloidogrel (3.03%), oxcarbamazeine(3.03%) and 
isoniazid (3.03%). Inducers of CYP3A4 enzyme present in the prescritions were 
phenytoin (55.88%) and rifampicin (44.11%). The study reviewed the strength of 
inhibition/induction of metabolism of the CY3A4 substrate by the 
inhibitors/inducers. Mechanism of these interactions as well as the severity and 
clinical significance of interactions were also reviewed using relevant literatures. 
A suitable therapeutic alternative was recommended whenever a possibility of 
major drug-drug interaction between CY3A4 substrate and inhibitor/inducer was 
observed in the study.    
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ABBREVIATIONS 
 
ADR              :  Adverse drug reactions 
AERS              :      Adverse Event Reporting System 
AUC           :      Area under curve 
ATP   : Adenosine triphosphate 
ADP               :  Adenosine diphosphate 
ACS :  Acute coronary syndromes 
AEDs  : Anti epileptic drugs 
ARBs   : Angiotensin receptor blockers 
ARF : Acute Renal Failure 
ATN : Acute Tubular Necrosis 
B.P : Blood Pressure 
BMI : Body Mass Index 
CAD : Coronary Artery Disease 
CHF : Congestive heart failure 
COPD    : Chronic Obstructive Pulmonary Disease 
CYP      : Cytochrome 
CNS         : Central nervous system 
CL     : Clearance 
Abbreviations 
 
 
CI                  : Confidence interval 
 
CCB    : Calcium channel blockers 
CT                 : Computed tomography 
CVD             : Cardiovascular drugs 
CBZ            : Carbamazepine 
DMSO : Dimethyl sulphide 
DM : Diabetes Mellitus 
DI                   : Drug interaction 
eGFR : Estimated glomerular filtration rate 
ESRD : End Stage Renal Disease 
FDA                : Food and Drug administration 
GFR  : Glomerular Filtration Rate 
Hb : Haemoglobin 
HTN : Hypertension 
HMG COA      :   3-hydroxy- 3-methylglutaryl coenzyme A 
HIV  : Human immunodeficiency virus 
IHD : Ischemic Heart Disease 
MDRD : Modification of diet in renal disease 
MRI  : Magnetic Resonance Imaging 
ND : Nephrotoxic Drugs 
Abbreviations 
 
 
NSAIDs : Non-steroidal anti-inflammatory drugs 
 
NAMCS          : National Ambulatory Medical Care Survey 
OATP    : Organic anion transporting polypeptide 
PHT             : Phenytoin 
PPIs : Proton Pump Inhibitors 
PT  : Prothrombin Time 
PCI   : Percutaneous coronary intervention 
RBC : Red blood cells 
RBF : Renal Blood Flow 
RAAS : Renin Angiotensin Aldosterone System 
Scr : Serum Creatinine 
V/P      : Vancomycin/Piperacillin 
WBC : White Blood Cells 
WHO  : World Health Organization 
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INTRODUCTION 
DRUG INTERACTION 
 Drug interactions have been recognized for over 100 years. Today, with 
the increasing availability of complex therapeutic agents and widespread 
polypharmacy, the potential for drug interactions is enormous and they have 
become an increasingly important cause of adverse drug reactions (ADR).  
 An interaction is said to occur when the effects of one drug are altered by 
the co- administration of another drug, herbal medicine, food, drink or other 
environmental chemical agents. The net effect of the combination may manifest as 
an additive or enhanced effect of one or more drugs, antagonism of the effect of 
one or more drugs, or any other alteration in the effect of one or more drugs. 
 Clinically significant interactions refer to a combination of therapeutic 
agents which have direct consequences on the patient's condition. Therapeutic 
benefit can be obtained from certain drug interactions, for example, a combination 
of different antihypertensive drugs may be used to improve blood pressure control 
or an opioid antagonist may be use to reverse the effect of an overdose of 
morphine.  
 Most clinically important interactions involve the effect of one drug on the 
metabolism of another. Metabolism refers to the process by which drugs and other 
compounds are biochemically modified to facilitate their degradation and 
subsequent removal from the body. The liver is the principal site of drug 
metabolism, although other organs such as the gut, kidneys, lung, skin and 
placenta are involved. Drug metabolism consists of phase I reactions such as 
oxidation, hydrolysis and reduction, and phase II reactions, which primarily 
involve conjugation of the drug with substances such as glucuronic acid and 
sulphuric acid. Phase I metabolism generally involves the cytochrome P450 
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(CYP450) mixed function oxidase system. The liver is the major site of 
cytochrome 450-mediated metabolism, but the enterocytes in the small intestinal 
epithelium are also potentially important1. 
 The cytochrome P450 is a well known superfamily of isoenzymes that are 
responsible for the oxidative and reductive metabolic transformation of 
medications used in clinical practice. In addition, the CYP enzymes are commonly 
associated with causing many clinically relevant drug-drug interactions.   
 Of the CYP enzymes, CYP3A4 is not only the most prevalent CYP 
enzyme in the liver, but is used by more than 50% of medications for their 
metabolism and elimination from the body.  The CYP3A4 activity can be induced 
or it can be inhibited, thereby changing the drug concentrations present in the 
body and its pharmacokinetic profile. The isoforms of CYP3A in humans include 
3A3, 3A4, 3A5 and 3A7. Each of these enzymes share at least 85% amino acid 
sequence homology.  
 CYP3A4 is the predominant isoform of CYP3A in adult humans. It can 
catalyse a remarkable number of metabolic processes including aliphatic 
oxidation, aromatic hydroxylation, N-dealkylation, O-demethylation, S-
demethylation, oxidative deamination, sulfoxide formation, N-oxidation and N-
hydroxylation, to mention a few. This usually produces inactivation and 
elimination of most pharmaceuticals. However, it can also activate carcinogenic 
substances such as the aflatoxins and polycyclic aromatic hydrocarbons. Although 
CYP3A4 drug metabolising activity varies widely among individuals, it has a 
unimodal population distribution and does not appear to be subject to genetic 
polymorphism as is seen with other CYP isoforms (2D6, 2C9 and 2C19). The 
wide interindividual variability is likely, in part, to be caused by ethnic or cultural 
differences, perhaps related to an interaction between race and diet. Other factors 
known to play a role in activity are age and the presence of small bowel or liver 
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disease. There may be modest gender differences, perhaps related to the 
hormonalmilieu in which the enzyme functions, although this is controversial. 
CYP3A4 content is highest in the liver. Hepatic CYP3A4 content has been shown 
to vary at least 20-fold among individuals and activity, as measured by the 
erythromycin breath test, to range 10- fold. Small bowel CYP3A4 is found in the 
apical enterocytes and its content varies 11-fold among individuals. Hepatic and 
enteric CYP3A4 content appear to be regulated independently of each other. The 
location of CYP3A4 in the small bowel and liver makes it well suited to play a 
significant role in first-pass (or presystemic) drug metabolism. This is illustrated 
by the dihydropyridine calcium antagonist, felodipine, which is a CYP3A4 
substrate that normally undergoes sequential metabolism in the apical enterocytes 
of the small bowel and then in the hepatocytes of the liver following oral 
administration, resulting in a mean 15%absolute bioavailability2. 
CYP3A4 Substrate 
 A number of drugs from a broad range of therapeutic categories are 
CYP3A4 substrates. With regard to orally administered drugs, knowledge of the 
extent of, and factors determining, the bioavailability of these substrates allows 
for prediction of the changes that could occur to their pharmacokinetics with 
administration of a CYP3A4 inhibitor. Oral bioavailability (i.e. the fraction of the 
total dose that reaches the systemic circulation unchanged) is determined by 2 
major processes: the proportion of the dose that is absorbed from the gut and the 
fraction that does not undergo presystemic metabolism, mainly in the small bowel 
and liver. The contributions of enteric and hepatic metabolism can be estimated 
separately by determining drug clearance following both oral and intravenous 
administration. If a substrate normally has high presystemic elimination (low oral 
bioavailability) and is primarily dependent upon CYP3A4 for elimination, then 
administration of an inhibitor of its metabolism can be expected to produce 
substantial change in substrate pharmacokinetics under single dose conditions. 
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The interaction would be characterized by a higher drug peak plasma drug 
concentration (Cmax) from reduced presystemic metabolism and a greater area 
under the drug concentration-time curve (AUC) possibly from both lower 
presystemic and systemic elimination. 
 Furthermore, there seems to be an inverse relationship between the extent 
of inherent presystemic elimination and magnitude of the increase in Cmax and 
AUC among medications. This has been observed with dihydropyridines and 
grapefruit juice, benzodiazepines and ketoconazole, and 3-hydroxy- 3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors with itraconazole. 
The interaction appears to be different if the CYP3A4 substrate normally has a 
high oral bioavailability. In this setting, inhibition of first-pass metabolism in the 
small bowel and liver would not be expected to have much effect on the Cmax 
under single dose conditions. The AUC may be somewhat augmented as a result 
of prolongation of the apparent elimination half-life (t1⁄2β) from reduced systemic 
drug clearance. In this situation, repeat administration of CYP3A4 substrate and 
inhibitor may produce a cumulative increase in plasma substrate concentrations. 
Thus, the clinical importance of the inhibitory interaction for CYP3A4 substrates 
with high inherent oral bioavailability may be realized only during steady-state 
administration. With regard to intravenous therapy, this route of administration, 
by definition, results in complete drug bioavailability. Consequently, the 
pharmaco- kinetic characteristics of the interaction would probably be similar to 
those observed with a CYP3A4 substrate with high oral bioavailability. It should 
be noted that certain substrates metabolized by CYP3A4 are also substrates for P-
glycoprotein, a transmembrane adenosine triphosphate (ATP)-dependent active 
transport protein found in a number of organs, including the gut, brain, liver and 
kidney. P-glycoprotein acts as an efflux transporter to decrease drug absorption 
into the portal circulation and CNS and to increase drug elimination into the bile 
and urine. CYP3A4 and P-glycoprotein in the gut and liver appear capable of 
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acting in concert to decrease plasma drug concentrations. For those drugs that are 
substrates for both CYP3A4 and P-glycoprotein, inhibition of CYP3A4 or P-
glycoprotein might be expected to produce similar changes to the 
pharmacokinetics of the parent drug. Additionally, certain substances appear 
capable of inhibiting both CYP3A4 and P-glycoprotein. Consequently, some 
interactions originally thought to be caused solely by the inhibition of CYP3A4-
mediated drug metabolism are likely to be mediated, in part, by the inhibition of 
P-glycoprotein transport.  
List of CYP3A4 substrates 
Alfentanil  
Alfuzosin  
Almotriptan  
Alprazolam  
Amiodarone  
Amlodipine  
Aprepitant 
Atazanavir  
Atorvastatin  
Bepridil  
Bexarotene  
Bosentan  
Bromocriptine  
Budesonide  
Buprenorphine  
Bupropion  
Carbamazepine  
Ixabepilone  
Ketoconazole  
Lapatinib  
Levomethadyl  
Loperamide  
Lopinavir  
Loratadine 
Lovastatin  
Maraviroc  
Mefloquine 
Methylprednisolone 
Midazolam 
Mifepristone 
Modafinil  
Nefazodone 
Nevirapine  
Nicardipine  
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Cevimeline  
Cilostazol  
Cisapride  
Clarithromycin  
Clonazepam  
Clopidogrel 
Colchicine 
Cyclophosphamide 
Cyclosporine  
Dapsone  
Darunavir  
Dasatinib 
Delavirdine  
Dexamethasone  
Dihydroergotamine 
Diltiazem  
Disopyramide  
Docetaxel  
Donepezil  
Doxorubicin  
Droperidol 
Dutasteride  
Ebastine  
Efavirenz  
Eletriptan 
Eplerenone  
Ergotamine 
Nifedipine  
Nimodipine  
Nisoldipine  
Nitrendipine 
Oxybutynin  
Oxycodone  
Paclitaxel  
Paricalcitol 
Pimozide 
Pioglitazone 
Praziquantel  
Prednisolone 
Prednisone 
Propoxyphene 
Quazepam  
Quetiapine 
Quinacrine 
Quinidine 
Quinine 
Ranolazine  
Repaglinide 
Rifabutin  
Ritonavir  
Saquinavir 
Sibutramine 
Sildenafil  
Simvastatin 
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Erlotinib  
Erythromycin 
Estazolam 
Eszopiclone  
Ethinyl Estradiol 
Ethosuximide  
Etoposide  
Exemestane   
Felodipine  
Fentanyl  
Finasteride  
Flurazepam 
Fosamprenavir 
Galantamine  
Gefitinib  
Granisetron  
Halofantrine 
Ifosfamide  
Imatinib  
Indinavir  
Irinotecan  
Isradipine  
Itraconazole 
Sirolimus  
Solifenacin 
Sufentanil  
Sunitinib  
Tacrolimus 
Tadalafil  
Tamoxifen 
Tamsulosin 
Teniposide  
Testosterone 
Tiagabine  
Tinidazole 
Tipranavir 
Topiramate 
Triazolam 
Vardenafil 
Verapamil 
Vinblastine 
Vincristine  
Ziprasidone 
Zolpidem  
Zonisamide 
Zopiclone  
CYP3A4 Inhibitors 
 A wide variety of endogenous and exogenous substances has been 
identified as inhibiting CYP3A4 activity. Although these substances all share the 
common feature of interfering with CYP3A4 activity, they vary in potency and 
Introduction 
 
 
 
Inducers and Inhibitors of Cytochrome P450 3A4 Substrates  
and the Management of  their Drug Interactions  8 
mode of action. Many known inhibitors of CYP3A4 are of uncertain clinical 
relevance. However, specific inhibitors of CYP3A4 that deserve mention because 
they are potent and have been associated with clinically relevant interactions 
include azole antifungals, macrolide, antibacterials, nefazodone, the HIV protease 
inhibitors and grapefruit juice. Several mechanisms of inhibition are possible. 
Azole antifungals and first generation HIV protease inhibitors appear to act via 
competitive inhibition by rapid, reversible binding of the inhibitor or its 
metabolite to CYP3A4.Macrolide antibacterials produce slowly reversible, 
noncompetitive inhibition. This has been interpreted by some as mechanism based 
inhibition, but this does not appear to be the case. The furanocoumarins in 
grapefruit juice, dihydroxybergamottin and bergamottin, cause irreversible, 
mechanism-based (suicide) inhibition. This presumably involves CYP3A4-
mediated formation of a reactive metabolite that covalently binds to the enzyme, 
leading to its inactivation. Most potent orally administered inhibitors act at the 
level of the small bowel and liver. However, grapefruit juice is an example of an 
inhibitor that appears to be clinically active against only enteric CYP3A4 and may 
be useful as a probe of enteric CYP3A4 activity. Conversely, intravenous 
administration of a CYP3A4 inhibitor probably produces more selective action in 
the liver.  
 
 
 
List of CYP3A4 inhibitors 
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• Amiodarone 
• Anastrozole 
• Azithromzcin 
• Cannabinoids 
• Cimetidine 
• Clarithromycin 
• Clotrimazole 
• Cyclosporine 
• Danazol 
• Delavirdine 
• Dexamethasone 
• Diethyldithiocarbamate 
• Diltiazem 
• Dirithyromycin 
• Disulfiram 
• Entacapone (high dose) 
• Erythromycin 
• Ethinyl estradiol 
• Fluconazole 
• Fluoxetine 
• Fluvoxamine 
• Gestodene 
• Grapefruit juice 
• Indinavir 
• Isoniazid 
• Ketoconazole 
• Metronidazole 
• Mibefradil 
 
Miconazole 
• Nefazodone 
• Nelfinavir 
• Nevirapine 
• Norfloxacin 
• Norfluoxetine 
• Omeprazole 
• Oxiconazole 
• Paroxetine (weak) 
• Propoxyphene 
• Quinidine 
• Quinine 
• Quinupristine and dalfopristin 
• Ranitidine 
• Ritonavir 
• Saquinavir 
• Sertindole 
• Sertraline 
• Troglitazone 
• Troleandomycin 
• Valproic acid 
 
 
 
 
Drugs metabolised by cytochrome P450 (CYP) 3A4 and extent of  
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presystemic metabolism 
Presystemic 
metabolism 
Oral bioavailability 
(%) Drugs 
Very high <10 
Astemizole, buspirone, ergotamine, 
lovastatin, nimodipine, nisoldipine, 
saquinavir, 
simvastatin and terfenadine 
High 10-30 
Estradiola, atorvastatin, felodipine, 
indinavir, isradipine, nicardipine, 
nitrendipine, 
propafenonea and tacrolimus 
Intermediate 30-70 
Amiodaronea, amprenavir, 
carbamazepine, carvedilola, cisapride, 
cyclosporin, 
diltiazema, ethinylestradiol, etoposide, 
losartana, midazolam, nifedipine, 
nelfinavir, 
ondansetron, pimozide, sildenafila, 
triazolam and verapamila 
Low >70 
Alprazolam, amlodipine, dapsone, 
dexamethasone, disopyramide, 
donepezil, 
quinidinea, ritonavir and temazepam 
 
CYP3A4 Inducers 
 CYP3A4 inducers are drugs that increase the activity of CYP3A4. Note 
that the CYP3A4 enzyme is particularly susceptible to enzyme inducers, and 
marked reductions in the plasma concentrations of CYP3A4 substrates may occur. 
For example, a patient taking the potent CYP3A4 inducer rifampin may have a 
roughly 90% reduction in serum concentrations of CYP3A4 substrates, such as 
buspirone, triazolam, and verapamil3.  
 
List of CYP3A4 inducers 
Introduction 
 
 
 
Inducers and Inhibitors of Cytochrome P450 3A4 Substrates  
and the Management of  their Drug Interactions  11 
• Carbamazepine 
• Dexamethasone 
• Ethosuximide 
• Glucocorticoids 
• Griseofulvin 
• Phenytoin 
• Primidone 
• Progesterone 
• Rifabutin 
• Rifampin 
• Nafcillin 
• Nelfinavir 
• Nevirapine 
 
• Oxcarbazepine 
• Phenobarbital 
• Phenylbutazone 
• Rofecoxib (mild) 
• St John’s wort 
• Sulfadimidine 
• Sulfinpyrazone 
• Troglitazone 
 
 
 Many drugs commonly used in clinical practice are known substrates, 
inducers or inhibitors of CYP3A4 isoenymes but the severity of interaction 
depends upon the substrate sensitivity and the strength of induction or inhibition4. 
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LITERATURE REVIEW 
 Gandhi et al5 (2013) conducted a study on calcium-channel blocker–
clarithromycin drug interactions and acute kidney injury. This interaction resulted 
in acute kidney injury, hypotension when compared with azithromycin. The 
author concluded that among older adults taking a calcium-channel blocker, 
concurrent use of clarithromycin compared with azithromycin was associated with 
a small but statistically significant greater 30-day risk of hospitalization with acute 
kidney injury. These findings support current safety warnings regarding 
concurrent use of CYP3A4 inhibitors and calcium-channel blockers. 
 Sprave et al6 (2013) conducted a study on clinical studies of CYP3A4 and 
p-glycoprotein. The inductive property of rifampicin on four other CYP450 
enzymes, a probe drug and an endogenous biomarker were compared regarding 
their properties for measuring CYP3A4 activity. Induction was achieved by 
administration of rifampicin in three different doses (20-500 mg once daily) to 
healthy volunteers. The endogenous biomarker 4β-hydroxycholesterol had a linear 
relationship with the metabolic ratio of the CYP3A4 probe drug quinine. In this 
study four other probe drugs were also used simultaneously, each specific for a 
different CYP450 enzyme. All enzymes except CYP2D6 were induced by 
rifampicin. This cocktail had been designed not to cause any drug-drug 
interactions among the probes, which are also specific for each enzyme.  
The author concluded that the endogenous biomarker has some limitations 
compared to phenotyping with the probe drug. The half-life of  
4β- hydroxycholesterol is 17 days, which makes the method less suited for 
measuring rapid changes in enzyme activity. 
 Knibbe et al 7(2013) conducted a study on Drug Metabolism - The 
Importance of Cytochrome P4503A4. CYP3A4 is responsible for the metabolism 
of around 50% of the drugs. The latter involves the inactivation of the enzyme via 
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the formation of metabolic intermediates that bind irreversibly to the enzyme and 
then inactivate it. Medicines that are potent CYP3A4 inhibitors include 
clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir, and 
verapamil. Medicines that are potent inducers include phenobarbital, phenytoin 
and rifampicin. Many glucocorticoids in clinical use also induce CYP3A4.  
 Henneman et al8 (2012) performed a study on risk of hypotension with 
concomitant use of calcium-channel blockers and macrolide antibiotics. Both 
dihydropyridine and nondihydropyridine CCBs are CYP3A4 substrates. 
Potentially significant hypotension and shock may occour when macrolide 
antibiotics especially erythromycin and clarithromycin interact with calcium 
channel blocker. The author investigated that the frequency of hypotension as a 
result of concomitant CCB and macrolide administration appears to be small, but 
the risk of adverse effects and the severity of the effects appear to be greater for 
those patients who are older and in those with multiple Comorbidities. 
 Patel et al9 (2011) conducted a study on estimation of clinical 
pharmacokinetic interaction between atorvastatin and clopidogrel in 
atherosclerotic heart disease patients. This study was conducted by estimating the 
carboxylic acid clopidogrel metabolite level in blood serum and estimating the 
effect of atorvastatin on blood serum level of clopidogrel metabolite level. In this 
non randomized, prospective, crossover, single centric and open labeled study was 
carried out on patients (n=11) of atherosclerotic heart disease with or without PCI. 
The author investigated that Atorvastatin enhances the systemic bioavailability of 
clopidogrel. This might be due to the inhibition of intestinal P-gp function by 
atorvastatin and so clopidogrel efflux was reduced. This might have led to 
increased concentration of clopidogrel in systemic circulation. Therefore, 
concomitant use of clopidogrel with atorvastatin may require close monitoring for 
potential drug interactions. 
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 Eric et al10 (2011) conducted a study on Clopidogrel–Drug Interactions. 
Dual antiplatelet therapy with aspirin and clopidogrel is recommended treatment 
for percutaneous coronary intervention (PCI) and acute coronary syndromes 
(ACS). Whereas multidrug therapy with antiplatelet drugs, lipid-lowering and 
glucose-lowering agents, antihypertensive drugs, and even antidepressants has 
been suggested as a therapeutic strategy to reduce cardiovascular risk, multiple 
drug prescriptions increase the risk for drug– drug interactions. The author 
investigated that of prescribing a different platelet P2Y12 receptor inhibitor 
without known drug interactions. Another option is to prescribe a hydrophilic 
statin in place of atorvastatin; or pantoprazole or ranitidine, an H2RA not 
metabolized by CYP isoenzymes, in place of omeprazole. 
 Rowans et al11 (2009) reviewed a comparative case series of 
rhabdomyolysis reports associated with simvastatin and pravastatin. Domestic 
spontaneous reports were obtained from the FDA’s Adverse Event Reporting 
System (AERS). Drug utilization data were obtained from IMS HEALTH and the 
National Ambulatory Medical Care Survey (NAMCS). Adverse event reporting 
rates (AER) and ratios of rhabdomyolysis associated with simvastatin and 
pravastatin with and without stratification by CYP3A4 inhibitor concomitancy 
were determined. The author concluded that there is an increased risk of 
rhabdomyolysis during concomitant use of SV, a CYP3A4 substrate statin, and a 
CYP3A4 inhibitor. Additionally, the results support observations regarding 
muscle toxicity in simvastatin clinical trials with concomitant CYP3A4 inhibitors. 
 Jing et al12 (2009) reported that rifampicin alters atorvastatin plasma 
concentration on the basis of SLCO1B1 521TNC polymorphism. Both 
atorvastatin and rifampicin are substrates of OATP1B1 (organic anion 
transporting polypeptide 1B1) encoded by SLCO1B1 gene. Rifampicin is a potent 
inhibitor of SLCO1B and SLCO1B1 521TNC functional genetic polymorphism 
alters the kinetics of atorvastatin. Rifampicin might influence atorvastatin kinetics 
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in a SLCO1B1 polymorphism dependent manner. The author investigated that co-
administration of rifampicin and atorvastatin may significantly change atorvastatin 
pharmacokinetics in vivo, while this effect could vary according to SLCO1B1 
521TNC genotypes. Single oral dose of rifampicin significantly led to 5-fold 
increase of peripheral exposure of atorvastatin and the increase percentage of 
AUC (0–48) values were nearly triplesd in SLCO1B1 c.521TT participants 
compared with c.521CC carriers. 
 Molden et al13 (2008) performed a study on risk management of 
simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Co-prescription 
of the selected CYP3A4 inhibitors diltiazem, verapamil, clarithromycin, 
erythromycin, fluconazole, itraconazole and ketoconazole with either simvastatin 
or atorvastatin was detected with the aid of a simple computer programme. The 
author concluded that co-administration of cytochrome P450 (CYP) 3A4 
inhibitors with simvastatin or atorvastatin was associated with increased risk of 
developing myopathy or rhabdomyolysis.  
 Bhindi et al14 (2008) conducted a study on interaction between statins and 
clopidogrel. They have been shown to be safe as well as efficacious in a number 
of different clinical trials; however, studies have suggested that they can interact 
with other co-administered therapies. The author finally concluded that there is 
presently no compelling clinical evidence to stop co-administration of CYP3A4 
statins and clopidogrel, it is plausible that an important pharmacokinetic 
interaction exists, and further more robustly designed studies are needed to 
address this issue. 
 Foisy et al15 (2008) performed a study on adrenal suppression and 
Cushing’s syndrome secondary to an interaction between ritonavir and 
fluticasone. Ritonavir is a potent inhibitor of CYP3A4. Ritonavir co-
administration will lead to greater propensity to induce adrenal suppression. The 
author recommended to replace ritonavir with other antiretroviral drug while 
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maintaining fluticasone or substituting fluticasone with another inhaled or 
intranasal steroid or oral monteleukast. 
 Neuvonen et al16 (2006) performed a study on drug interactions with lipid-
lowering drugs. Simvastatin, lovastatin, and atorvastatin are metabolized by 
cytochrome P450 (CYP) 3A4. The interaction of statins with immunosuppersant 
drugs can lead to increase in plasma statin concentration which ultimately leads to 
muscle toxicity.  
 Saad et al17 (2006) performed a study on factors influencing the 
magnitude and clinical significance of drug interactions between Azole 
antifungals and selected immunosuppressants. Drug interactions between azoles 
and immunosuppressants are agent specific and depend on the potency of the 
azole inhibition of CYP3A4 and the plasma concentrations of each agent.  
 Castberg et al18 (2005) performed a study on prolonged pharmacokinetic 
drug interaction between terbinafine and amitriptyline. In vitro and in vivo studies 
have shown that terbinafine is a highly potent competitive inhibitor of CYP3A4. 
Concomitant use of terbinafine leads to an increase in serum concentration of 
amitriptyline. 
 Niwa et al19 2005 performed a study on effect of antifungal drugs on 
cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 Activities in Human Liver 
Microsomes. The study compared the effects of five antifungal drugs on specific 
activities by CYP1A2, CYP2D6, and CYP2E1 in human liver microsomes under 
the same experimental conditions. In addition, the effect of preincubation was 
estimated in order to investigate whether these antifungal drugs are the 
mechanism-based inhibitors. The author concluded that CYP1A2, CYP2D6, and 
CYP2E1 are inhibited only by miconazole, whereas the inhibition by other 
antifungal drugs was not observed. In addition, the antifungal drugs investigated 
are not suggested to be the mechanism-based inhibitors.  
 Strandell et al20 2005 performed a study on interaction between statins 
and azithromycin interaction. The individual case reports in VigiBase and the 
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original files were reviewed. In order to investigate the reporting over time for 
rhabdomyolysis with azithromycin and statins to VigiBase, Omega values were 
generated retrospectively. Rhabdomyolysis under concomitant use of 
azithromycin and statins was reported more often than expected from 2000 and 
onwards in Vigibase. The author concluded that interactions between 
azithromycin and statins resulting in rhabdomyolysis may occur. 
 Serebruany et al21 (2004) conducted a study on absence of interaction 
between atorvastatin or other statins and clopidogrel. Some, but not all, post hoc 
analyses have suggested that the antiplatelet effects of clopidogrel are inhibited by 
atorvastatin. We sought to address this issue prospectively by performing serial 
measurements of 19 platelet characteristics using conventional aggregometry, 
rapid analyzers, and flow cytometry. The author investigated that statins in 
general, and atorvastatin in particular, do not affect the ability of clopidogrel to 
inhibit platelet function in patients undergoing coronary stenting. The prospective 
data also suggest that statins may inhibit platelets directly via yet unknown 
mechanism possibly related to the regulation of the PAR-1 thrombin receptors. 
 Gennere et al22 2004 conducted a study on Regulation of CYP3A4 by the 
bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. 
Experiments performed in vitro in different cell culture systems, gel-mobility shift 
assays and experiments performed in vivo in transgenic mice lacking FXR or PXR 
and treated with the synthetic FXR agonist GW4064 were undertaken to study the 
implication of FXR in the regulation of CYP3A4. The author concluded that 
although elevated concentrations of precursors of bile acids and secondary bile 
acids elicit CYP3A activation via PXR, primary bile acids, at only a slightly 
increased or even at physiological concentration, may modulate the expression of 
CYP3A via FXR.  
 Hesse et al23 (2003) carried out a study on clinically important drug 
interactions with Zopiclone, Zolpidem and Zaleplon. Potent CYP3A4 inhibitors 
such as ketokonazole, itraconazole and erythromycin increases the area under the 
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curve of zolpidem ,zapiclone by 1.5 to 2 fold. The authors concluded that a 
reduction of 50% of the hypnotic dose may lead to decrease in the adverse 
reactions. 
 Cheung et al24 (2001) carried out a study on inhibition of CYP3A4 
activity by grape fruit flavanoids, furanocoumarins and other related cpompounds. 
The effect of various flavanoids and furanocoumarin derivatives on CYP3A4 
activity in two human liver microsomal samples was determined using quinine as 
a substrate. All flavanoids and furanocoumarins derivatives were dissolved in 
DMSO. In all cases inhibition activities were compared with activities in control 
incubation containing 0.2 % (v/v) DMSO. The author concluded that more than 
one component present in grape fruit juice may contribute to the inhibitory effect 
on CYP3A4. Bergapten appears to be a potent inhibitor of CYP3A4 and may 
therefore be primarily responsible for the effect of grapefruit juice. 
 Andrew et al25 (2001) performed a study on Effect of amlodipine on 
platelet inhibition by clopidogrel in patients with ischaemic heart disease: a 
randomised, controlled trial. Amlodipine inhibits cytochrome P450 (CYP) enzyme 
and has the potential to reduce clopidogrel bioactivation in vivo. Reports in 
previous retrospective studies described greater platelet reactivity in patients on 
amlodipine. The author concluded that amlodipine does not significantly attenuate 
the antiplatelet effect of clopidogrel in patients with ischaemic heart disease with 
respect to pharmacological end-points. The common practice of concomitant use 
of these two drugs may be continued. 
 Ogu et al26 (2000) conducted a study on drug interactions due to 
cytochrome P450. Cyclosporine, tacrolimus, and carbamazepine are all substrates 
of CYP3A4. Another drug class of note in this category is the 3-hydroxy- 3-
methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors. High serum 
concentrations of some of these agents are strongly linked to the development of 
rhabdomyolysis. Adding a CYP3A4 inhibitor to a drug regimen that includes 
Literature Review 
 
 
 
Inducers and Inhibitors of Cytochrome P450 3A4 Substrates  
and the Management of  their Drug Interactions  19 
certain HMG CoA reductase inhibitors greatly increases the patient's risk of 
developing rhabdomyolysis. One advantage of recognizing this drug interaction 
has been the subsequent studies conducted to identify which agents can be used 
safely in multidrug combinations. Research focusing on CYP3A4 inhibitors and 
HMG CoA reductase inhibitors has found that pravastatin and fluvastatin can be 
coadministered with itraconazole, a potent CYP3A4 inhibitor, without significant 
changes in maximum serum concentrations. 
 Kenworthy et al27 (1999) performed a study on CYP3A4 drug 
interactions: correlation of 10 in vitro probe substrates. The effects of 34 
compounds on CYP3A4-mediated metabolism were investigated in a recombinant 
CYP3A4 expression system. Inhibition of erythromycin, dextromethorphan and 
diazepam N-demethylation, testosterone 6b-hydroxylation, midazolam  
1-hydroxylation, triazolam 4-hydroxylation, nifedipine oxidation, cyclosporin 
oxidation, terfenadine C-hydroxylation and N-dealkylation and 
benzyloxyresorufin O-dealkylation was evaluated at the apparent Km or S50 (for 
substrates showing sigmoidicity) value for each substrate and at an inhibitor 
concentration of 30 mm. The author finally investigated that multiple CYP3A4 
probes, representing each substrate group, are used for the in vitro assessment of 
CYP3A4-mediated drug interactions. 
 Meyer et al28 (1996) performed a study on metabolic interaction of proton 
pump inhibitors with other drugs. Proton pump inhibitors are strongly metabolized 
by CYP3A4 enzyme. Interaction with anti-psychotic drugs has been carried out in 
this study. The authors investigated that proton pump inhibitors increases the 
hypnotic drug concentration in the plasma. 
 
 Guengerich et al29 (1990) conducted a study on clinically significant drug 
interaction with the cytochrome P450 enzyme system. The CYP450 enzyme 
system is a key pathway for drug metabolism. When either drug is co-
administered with an inhibitor of CYP3A4, such as an azole antifungal medication 
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or macrolide antibiotic, a build-up of the parent compound takes place, resulting 
in toxicity. Cetirizine has not been found to have clinically significant drug 
interactions with the CYP3A4 inhibitors erythromycin, azithromycin, 
ketoconazole or low-dose theophylline. Erythromycin and clarithromycin, both 
potent inhibitors of CYP3A4, can inhibit the metabolism of drugs which are 
metabolized by CYP3A (e.g., astemizole, cisapride and theophylline). Statins that 
are substrates of CYP3A4 have the greatest potential for interacting with drugs 
known to inhibit the CYP450 system, increasing the concentrations of substrate 
and the potential for adverse drug interactions. 
 Backman et al30 (1989) performed a study on concentrations and effects 
of oral midazolam are greatly reduced in patients treated with carbamazepine or 
phenytoin. First studied the pharmacokinetic and pharmacodynamic aspects of an 
oral 15-mg dose of midazolam in 6 patients with epilepsy who are also taking 
carbamazepine (CBZ) or phenytoin (PHT). Then compared results with those 
obtained in 7 no induceds control subjects. Plasma concentrations and effects of 
midazolam were measured for 10 h. the author investigated that Midazolam is 
extensively metabolized by CYP3A enzymes during first-pass and elimination 
phases, and its oral bioavailability is normally <50%. When midazolam is 
administered intravenously or intramuscularly to treat such conditions as status 
epilepticus, it bypasses the altered presystemic metabolism and its 
pharmacokinetics is not affected to the same extent as after oral administration. 
However, during continuous administration of intravenous or intramuscular 
midazolam, larger than normal doses are probably needed in patients taking AEDs 
because the hepatic clearance of midazolam is increased.  Larger than usual oral 
doses of midazolam would be needed to produce any hypnotic effects in patients 
receiving chronic AED therapy. Because of variability in the extent of this 
interaction, other hypnotic drugs may be preferable in patients taking AEDs. 
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SCOPE OF THE STUDY 
 The cytochrome P450 is a well known super family of isoenzymes that are 
responsible for the oxidative and reductive metabolic transformation of 
medications used in clinical practice. In addition, the CYP enzymes are commonly 
associated with causing many clinically relevant drug-drug interactions.  Of the 
CYP enzymes, CYP3A4 is not only the most prevalent CYP enzyme in the liver, 
but is used by more than 50% of medications for their metabolism and elimination 
from the body.  The CYP3A4 activity can be induced or it can be inhibited, 
thereby changing the drug concentrations present in the body and its 
pharmacokinetic profile2.  
 It is also important to note that all medications within a particular drug 
class do not have the same effect on CYP3A4 substrates.  For example, within the 
macrolide antibiotics, all of them are known inhibitors of CYP3A4 with the 
exception of azithromycin.  For the calcium channel blockers, it is only the non-
dihydropyridine calcium channel blockers that are known inhibitors of CYP3A4, 
but not amlodipine or nifedipine. Lastly, within the fluoroquinolone antibiotics, 
ciprofloxacin is a strong inhibitor of CYP3A4 while levofloxacin is a weak 
inhibitor.  This is important as it reveals that the pharmacokinetic profiles do not 
always completely follow a class effect3.  
 Many drugs commonly used in clinical practice are known substrates, 
inducers or inhibitors of CYP3A4 isoenymes but the severity of interaction 
depends upon the substrate sensitivity and the strength of induction or inhibition. 
 A strong inhibitor is one that causes a > 5-fold increase in the plasma AUC 
values or more than 80% decrease in clearance of CYP substrates in clinical 
evaluations. A moderate inhibitor is one that caused a > 2- but < 5-fold increase in 
the AUC values or 50- 80% decrease in clearance of sensitive CYP substrates 
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when the inhibitor is given at the highest approved dose and the shortest dosing 
interval in clinical evaluations. A weak inhibitor is one that causes a > 1.25 – but 
 < 2-fold increase in the AUC values or 20-50% decrease in clearance of sensitive 
CYP substrates when the inhibitor is given at the highest approved dose and the 
shortest dosing interval in clinical practice. 
 Sensitive substrates are drugs that demonstrate an increase in AUC of 
 ≥5-fold with strong index inhibitors of a given metabolic pathway in clinical 
drug-drug studies. Moderate sensitive substrates are drugs that demonstrate an 
increase in AUC of ≥2 to <5-fold with strong index inhibitors of a given metabolic 
pathway in clinical drug-drug interaction studies31.  
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OBJECTIVE 
 To study various inducers and inhibitors of CYP3A4 substrates in clinical 
practice and to follow a mechanism based approach in their management of drug-
drug interactions 
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PLAN OF THE STUDY 
 The proposed study entitled “Inducers and inhibitors of Cytochrome P450 
3A4 substrates and the management of their drug interactions” was planned and 
carried out as given below. 
Phase I: 
 Identification of research problems and scope of the study. 
 Preparation of study protocol. 
 Obtaining consent from the hospital authorities. 
 Literature survey. 
Phase II: 
 Design of structured performance. 
 Patient selection, inclusion/exclusion criteria. 
 Data retrieval from general medicine department. 
 Evaluation of prescription for possible drug-drug interaction based on 
CYP3A4 metabolism and pharmacist recommendation. 
Phase III: 
 Data analysis 
 Report submission 
 
Methodology 
 
 
 
Inducers and Inhibitors of Cytochrome P450 3A4 Substrates  
and the Management of  their Drug Interactions  25 
METHODOLOGY 
 
Study Site 
 General medicine department of a 750 bedded multispecialty tertiary care 
teaching hospital. 
Study Design  
 Prospective observational study 
Study Duration  
 10 months from November 2016 to August 2017. 
Inclusion criteria  
 Prescriptions from the General Medicine Department during the study period 
and having at least one CYP3A4 enzyme substrate along with an inducer or inhibitor 
are included in the study 
Exclusion criteria  
 Prescriptions with no CYP3A4 substrates are excluded from the study. 
Consent from the hospital authorities 
It is mandatory that every project work carried out in the hospital has to be 
approved by the Institutional Ethical Committee of hospital. A protocol of the 
proposed study which includes the objectives, methodology and probable outcomes 
was prepared and submitted to the Institutional Ethical Committee of the study 
hospital. The approval from the committee was obtained as a letter [SRH/EC.9-
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8/2017-18 dated 25TH February 2017] and the same was given in Annexure No.1 
for reference. The author was permitted to utilize the hospital facilities to make a 
follow up of the cases, in the selected departments. All the health care professionals 
of the study site were well informed through Dean’s official circular. 
Design of Patient Information Form 
A patient information form has been prepared to inform the patients and care 
givers of patients about the purpose, necessity of the study assuring them that the 
confidentiality will be strictly maintained and this is for only the betterment of 
patient’s health. The format includes the details like Department address, name and 
signature of the investigator and supervisor, date, place and details of the study. The 
model of the patient information form was given in the Annexure No.: 2 for 
reference. 
 
Design of Patient Consent Form 
A patient consent form has also been prepared to obtain written consent from 
all the patient or bystander and will be included in the study. The format contains 
details like address, date, place, provision for signature of the patient or bystander, 
investigator and supervisor. The same was given in the Annexure No.: 3 for 
reference. 
 
Design of Data Entry Form 
 A separate data entry form was also designed for collecting the data related to 
patients including name, age, gender, height, weight, IP. No., date of admission, date 
of discharge, vital signs, reason for admission, past medical history and past 
medication history. Provision was also given in the format for entry of clinical lab 
data like blood counts, liver function test, renal function test, pulmonary function test, 
electrolytes, urine examination, diagnosis, drug chart, and drug interaction chart and 
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any interventions. The data entry form also had details of CYP3A4 substrates, 
inhibitors, inducers and relating drug interactions with respect to each prescription. 
The model of a patient data entry form is given in the Annexure No.: 4 for reference. 
 
Sample Size 
 A sample size of 100 patients. 
 
Method 
            Demographic characteristics of the patients such as age, gender, date of 
admission, date of discharge were recorded in customized data entry forms. Their 
major diagnosis, co-morbid conditions, prescribed medications, their strength and 
dosing schedule were also noted down during daily ward rounds. Cytochrome P450 
3A4
 
substrates, their inducers or inhibitors present in the prescription were identified 
using Micromedex database. The sensitivity of the substrate to the inhibitor or 
inducer as well as the strength of enzyme induction or inhibition is studied using the 
above mentioned database, Medline and Pubmed search.  
 A strong inhibitor is one that causes a > 5-fold increase in the plasma AUC 
values or more than 80% decrease in clearance of CYP substrates in clinical 
evaluations. A moderate inhibitor is one that caused a > 2- but < 5-fold increase in the 
AUC values or 50- 80% decrease in clearance of sensitive CYP substrates when the 
inhibitor is given at the highest approved dose and the shortest dosing interval in 
clinical evaluations. A weak inhibitor is one that causes a > 1.25 - but < 2-fold 
increase in the AUC values or 20-50% decrease in clearance of sensitive CYP 
substrates when the inhibitor is given at the highest approved dose and the shortest 
dosing interval in clinical practice. 
Methodology 
 
 
 
Inducers and Inhibitors of Cytochrome P450 3A4 Substrates  
and the Management of  their Drug Interactions  28 
 Sensitive substrates are drugs that demonstrate an increase in AUC of ≥5-fold 
with strong index inhibitors of a given metabolic pathway in clinical drug-drug 
studies. Moderate sensitive substrates are drugs that demonstrate an increase in AUC 
of ≥2 to <5-fold with strong index inhibitors of a given metabolic pathway in clinical 
drug-drug interaction studies31. 
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RESULTS 
 Prescriptions of 100 patients from the General Medicine department were 
evaluated for CYP3A4 based drug-drug interactions. All the selected prescriptions 
had at least one CYP3A4 enzyme substrate along with an inducer or inhibitor. The 
mean age group of study subjects was 53.12±15.13 years. Fifty five of them were 
male patients. Duration of hospital stay of different age groups varied between 
5.38±1.19 days to 6.80±1.30 days. Number of drugs prescribed in patients of 
different age groups ranged from 9.33±4.04 to 15.11±3.32. Demographic details 
of patients are shown in table 1. 
 Major diagnosis observed in study population were hypertension (21%) 
followed by diabetes mellitus (14%), chronic renal failure (12%), tuberculosis 
(9%), viral fever (7%), ischemic heart disease (7%) and others. Major diagnosis 
and various co morbid conditions of study populations are shown in table 2 and 3 
respectively. 
 Nine hundred and twenty five drugs belonging to Eighty eight categories 
were prescribed in the study subjects. Of these, vitamins and minerals (33.63%), 
antibiotics (12.5%), antihypertensives (9.09%), antiulcer drugs (6.81%), 
antiepileptics (6.81%) and anticoagulants (6.81%) were most frequently 
prescribed. Table 4 and 5 summarizes the details of drugs prescribed. 
 Hundred substrates, 66 inhibitors and 34 inducers of CYP3A4 were 
identified during the study period. The substrates included clopidogrel (47%), 
atorvastatin (22%), esomeprazole (13%), omeprazole (5%) domperidone (4%), 
midazolam (3%), phenytoin (2%) and azithromycin (2%). The various inhibitors 
of CYP3A4 isoenzymes recorded during the current study were atorvastatin 
(45.45%), amlodipine (19.69%), esomeprazole (12.12%), amiodarone (7.57%), 
flucaanazole (6.06%), cloidogrel (3.03%), oxcarbamazeine (3.03%) and isoniazid 
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(3.03%). Inducers of CYP3A4 enzyme present in the prescritions were phenytoin 
(55.88%) and rifampicin (44.11%). Table 6 shows the list of CYP3A4 substrates, 
and inhibitors as well as inducers of CYP3A4 based metabolism. The study 
identified sixty six inhibitors and 34 inducers of CYP3A4 enzyme. Interacting 
drug combinations of various substrates and inhibitors of CYP3A4 are 
summarized in table 7. Table 8 summerizes the details of substrates and inducers 
of CYP3A4 mediated metabolism. Table 7 and 8 also presents the strength of 
inhibition/induction, mechanism of interaction, severity of interaction, possible 
effect of interaction based on available reports and pharmacist’s 
recommendations. 
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TABLE 1: DEMOGRAPHIC DETAILS (n = 100) 
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1 CHILDHOOD (1-12) 0 
 
53.12 
±15.13 
 
 
 
Male 
55 
 
 
 
 
 
 
Female 
45 
0 0 
2 ADOLESCENT (13-18) 5 
 
6.80 
±1.30 
 
9.33 
±4.04 
3 
EARLY 
ADULTHOOD 
(19-35) 
16 6.44 
±1.51 
13.42 
±1.88 
4 ADULTHOOD (36-50) 21 
6.19 
±1.50 
14.61 
±1.41 
5 
LATE 
ADULTHOOD 
(51-65) 
39 5.87 
±1.36 
15.11 
±3.32 
6 
YOUNG 
ADULTHOOD 
(66-74) 
13 5.38 
±1.19 
10.14 
±4.22 
7 
OLD 
ADULTHOOD 
(75-84) 
6 6.17 
±1.96 
12.01 
±4.69 
8 OLD AGE (85-95) 0 0 0 
 
 
 
 
 
 
 
TABLE 2 : MAJOR DIAGNOSIS OBSERVED IN THE STUDY                   
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POPULATION (n=100) 
SL NO MAJOR DIAGNOSIS NO OF PATIENTS PERCENTAGE 
1 HYPERTENSION 21 21 
2 DIABETES MELITUS 14 14 
3 CHRONIC RENAL FAILURE 12 12 
4 TUBERCULOSIS 9 9 
5 VIRAL FEVER 7 7 
6 ISCHEMIC HEART DISEASE 7 7 
7 HYPERLIPIDEMIA 6 6 
8 UTI 4 4 
9 MIOCARDIAL INFARCTION 4 4 
10 CHRONIC KIDNEY DISEASE 3 3 
11 SEIZURE 2 2 
12 COPD 2 2 
13 DENGUE FEVER 2 2 
14 ULCER 1 1 
15 VIRAL PYREXIA 1 1 
16 RHEUMATIC HEART DISEASE 1 1 
17 STROKE 1 1 
18 CORONARY HEART DISEASE 1 1 
19 PNEUMONIA 1 1 
TABLE 3: VARIOUS CO-MORBID CONDITIONS OBSERVED IN THE 
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STUDY POPULATION (n=92) 
SL NO. CO-MORBIDITY NO OF PATIENTS PERCENTAGE 
1 DIABETES MELITUS 24 26.08 
2 HYPERTENSION 17 18.47 
3 HYPOTHYROIDISM 6 6.52 
4 GASTRITIS 6 6.52 
5 ISCHEMIC HEART DISEASE 5 5.43 
6 HYPERLIPIDEMIA 4 4.34 
7 CHRONIC RENAL FAILURE 4 4.34 
8 PEPTIC ULCER 4 4.34 
9 ACUTE INFARCT 3 3.26 
10 PNEUMONIA 2 2.17 
11 ANXIETY 2 2.17 
12 SEIZURE 2 2.17 
13 CHRONIC KIDNEY DISEASE 2 2.17 
14 HEPATITIS 1 1.08 
15 OTHERS 19 20.65 
 
 
 
 
 
TABLE 4: DRUG CATEGORIES (n=88) 
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SL 
NO DRUG CATEGORIES 
NO OF 
PATIENTS 
NO OF 
DRUGS PERCENTAGE 
1 VITAMINS AND MINERALS 63 12 13.63 
2 ANTIBIOTICS 41 11 12.5 
34 ANTIHYPERTENSIVES 57 8 9.09 
5 ANTIULCER DRUGS 64 6 6.81 
6 ANTIEPILEPTICS 14 6 6.81 
7 ANTICOAGULANTS 51 6 6.81 
8 ANTIHYPERLIPIDEMIC DRUGS 34 4 4.54 
9 HYPOGLYCEMIC AGENTS 58 4 4.54 
10 DIURETICS 12 3 3.40 
11 ANALGESICS 12 3 3.40 
12 HORMONES 18 3 3.40 
13 ANTIASTHMATICS 10 3 3.40 
14 ANTITUBERCULAR AGENTS 9 2 2.27 
15 ANTIEMETICS 34 2 2.27 
16 ANTIINFLAMATORY AGENTS 11 2 2.27 
17 ANXIOLYTICS 12 2 2.27 
18 ANTIDIARRHOEALS 4 2 2.27 
19 ANTI ANGINAL DRUGS 5 2 2.27 
20 LAXATIVES 4 2 2.27 
21 ANTACIDS 10 1 1.13 
22 ANTI VERTIGO AGENTS 5 1 1.13 
23 ANTIGOUT AGENTS 2 1 1.13 
24 SEDATIVES 2 1 1.13 
25 ANTIFUNGAL DRUGS 8 1 1.13 
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TABLE 5: DETAILS OF DRUGS PRESCRIBED (N = 925) 
 
SL 
NO DRUG CATEGORY 
NAME OF THE 
DRUG 
NO OF 
DRUGS PERCENTAGE 
1 
VITAMINS AND 
MINERALS 
Calcitrol 57 6.16 
2 Vitamin 
supplements 43 4.64 
3 Methylcobalamin 38 4.10 
4 Alphaketoanalogue 25 2.70 
5 Calcium acetate 24 2.59 
6 Alfacalcidol 13 1.40 
7 Calcium 13 1.40 
8 Calcium carbonate 12 1.29 
9 Folic acid 9 0.97 
10 Calcium Gluconate 4 0.43 
11 Iron 3 0.32 
12 Pregabalin 2 0.21 
1 
ANTIBIOTICS 
Piperacillin 
sodium+tazobactu
m 
32 3.45 
2 Pre –probiotics 20 2.16 
3 Ceftriazone + 
sulbactam 11 1.18 
4 Cefixime 6 0.64 
5 Amoxicillin+clavul
anic acid 4 0.43 
6 Azithromycin 4 0.43 
7 Ceftriazone 3 0.32 
8 Linezolid 3 0.32 
9 Tetracyclines 1 0.10 
10 Trimethoprim + Sulfamethoxazole 1 0.10 
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SL 
NO DRUG CATEGORY 
NAME OF THE 
DRUG 
NO OF 
DRUGS PERCENTAGE 
11 Carbapenem 1 0.10 
1 
ANTIHYPERTEN-
SIVES 
Telmisartan 43 4.64 
2 Amlodipine 13 1.40 
3 Nebivolol 5 0.54 
4 Cardevilol 3 0.32 
5 Verapamil 2 0.21 
6 Clinidipine 2 0.21 
7 Nifedipine 2 0.21 
8 Propanolol 1 0.10 
1 
ANTIULCER  
DRUGS 
Pantoprazole 87 9.40 
2 Sucralfate 14 1.51 
3 Rabeprazole 10 1.08 
4 Esomeprazole 10 1.08 
5 Omeprazole 12 1.29 
6 Ranitidine 9 0.97 
1 
ANTIHYPERLIPID
EMIC DRUGS 
Atorvastatin 38 4.10 
2 Trimetazidine 2 0.21 
3 rosuvastatin 3 0.32 
4 Rosuvastatin + 
Fenofibrate 1 0.10 
 
1 
HYPOGLYCEMIC 
AGENTS 
Insulin 29 3.13 
2 Metformin 25 2.70 
3 Glimepiride + Metformin 2 0.21 
4 Glimipride 8 0.86 
 
 
SL 
NO 
DRUG CATEGORY NAME OF THE 
DRUG 
NO OF 
DRUGS 
PERCENTAGE 
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1 
ANTICOAGULANTS 
Clopidogrel 58 6.27 
2 Aspirin 7 0.75 
3 Asprin+clopidogrel 14 1.51 
4 Enoxaparin Sodium 4 0.43 
5 Warfarin 2 0.21 
6 Heparin 2 0.21 
1 ANTACIDS Sodium bicarbonate 2 0.21 
1 ANTIGOUT AGENTS febuxostat 2 0.21 
1 
ANTIEMETIC S 
Ondansetron 25 2.70 
2 Ramosetron 4 0.43 
1  Torsemide 4 0.43 
2 
DIURETICS 
Furosemide 15 1.62 
3 Spiranolactone 3 0.32 
1 
ANTIINFLAMATOR
Y AGENTS 
Paracetamol 5 0.54 
2 Tramadol 5 0.54 
3 Paracetamol + Tramadol 2 0.21 
SL 
NO DRUG CATEGORY 
NAME OF THE 
DRUG 
NO OF 
DRUGS PERCENTAGE 
1 HORMONES  Levothyroxine 4 0.43 
2 Prednisolone 7 0.75 
3 Methyl 
prednisolone 
5 0.54 
1 ANTIEPILEPTICS  Phenytoin 16 1.72 
2 Clobazam 2 0.21 
3 Flunarazine 2 0.21 
4 Oxcabazepine 4 0.43 
5 Fosphenytoin 2 0.21 
6 Clonazepam 1 0.10 
1 ANTIASTHMATIC Etophylline+theoph 8 0.86 
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DRUGS  ylline 
2 Acebrophylline 2 0.21 
3  Salbutamol 16 1.72 
1 ANTI 
INFLAMMATORY  
AGENTS 
Chymotrypsin 4 0.43 
2 
Tramadol 
4 0.43S 
1 ANXIOLYTICS  Midazolam  1 0.10 
2 Alprazolam 5 0.54 
1 ANTIVERTIGO  
AGENTS Betahistine 
2 0.21 
1 ANTIDIARRHOELS Vibact 4 0.43 
2 Racecadotril 5 0.54 
1 ANTITUBERCULA
R AGENTS 
Rifampicin 9 0.97 
2 Isoniazid + 
Rifampicin 
7 0.75 
1 ANTI ANGINALS Nitroglycerine 6 0.64 
2 Isosorbide dinitrite 4 0.43 
ss1 LAXATIVES Lactulose 2 0.21 
2 Liquid paraffin 1 0.10 
1 ANTIFUNGAL 
DRUGS  
Fluconazole 9 0.97 
1 SEDATIVES Zolpidem 2 0.21 
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Table 6: Substrates, Inhibitors and Inducers of CYP3A4 Isoenzymes Present In the Prescriptions 
SL 
NO. SUBSTRATES NO % INHIBITORS NO % INDUCERS NO % 
1 Clopidogrel  47 47 Atorvastatin 30 45.45 Rifampicin  19 55.88 
2 Atorvastatin  22 22 Amlodipine 13 19.69 
3 Esomeprazole  13 13 Esomeprazole 8 12.12 
4 Omeprazole  5 5 Amiodarone 5 7.57 
5 Domperidone  4 4 Flucanazole  4 6.06 Phenytoin  15 44.11 
6 Midazolam  3 3 Clopidogrel  2 3.03 
7 Phenytoin  2 2 Oxcarbamazepine 2 3.03 
8 Azithromycin  2 2 Isoniazid  2 3.03 
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 Table 7: Substrates and Inhibitors of CYP3A4 mediated metabolism (n=66) 
Substrate Precipitant No. % Strength of Inhibition 
Strength of 
Substrate Mechanism of Interaction 
Severity of 
Interaction Effect of Interaction Pharmacist Recommendation 
Clopidogrel Atorvastatin 26 39.39 Strong inhibitor 
Sensitive 
substrate 
Competition with CYP3A4 
mediated metabolism and 
inhibition of p-glycoprotein 
efflux transport of clopidogrel by 
CYP3A4 metabolized statins. 
Major 
Results in decreased 
formation of clopidogrel 
active metabolite in plasma 
finally resulting in high on 
treatment platelet activity 
Discontinue the current statin and 
substitute with the statin that is  not 
metabolized by 
CYP3A4(pravastatin, rosuvastatin) 
Clopidogrel Amlodipine 11 16.66 - - 
Inhibition of CYP3A4 mediated 
clopidogrel activation by 
amlodipine 
Major 
Results in increased plasma 
concentration of 
clopidogrel and decreased 
antiplatelet effect 
The addition of cilostazol may 
reduce the potentially harmful 
interaction. 
Clopidogrel Esomeprazole 7 10.60 - - 
Inhibition of CYP2C19 and 
CYP3A4 mediated clopidogrel 
metabolism to active metabolite 
by esomeprazole 
Moderate 
Concurrent use may result 
in reduced plasma 
concentration of 
clopidogrel active 
metabolite 
Instead of esomeprazole use 
pantaprazole as it has less effect on 
antiplatelet activity. 
Atorvastatin Amiodarone 5 7.57 - - Inhibition of CYP3A4 mediated 
atorvastatin metabolism Moderate 
Concurrent use may result 
in an increased risk of 
myopathy or rhabdomylosis 
Monitor creatinine kinase levels. 
Consider substuting other 
HMGCoA reductase inhibitors 
such as pravastatin or rosuvastatin. 
Esomeprazole Flucanazole 4 6.06 Moderate inhibitor 
Moderately 
sensitive 
substrate 
Inhibition of CYP3A4 mediated 
esomeprazole metabolism by 
flucanazole. 
Moderate 
Results in increased 
esomeprazole plasma 
concentration 
Avoid concomitant use of both 
these drugs. Patients should be 
monitored for potentially increased 
adverse effects of PPIs during co-
administration. 
Phenytoin Clopidogrel 2 3.03 - - 
Inhibition of CYP2C19 and 
CYP3A4 mediated phenytoin 
metabolism by clopidogrel 
Moderate 
Results in increase plasma 
concentration of phenytoin 
and phenytoin toxicity. 
Avoid concomitant use of both 
these drugs. 
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Substrate Precipitant No. % Strength of Inhibition 
Strength of 
Substrate Mechanism of Interaction 
Severity of 
Interaction Effect of Interaction Pharmacist Recommendation 
Phenytoin Oxcarbama- Zepine 2 3.03 
Moderate 
inhibitor 
Moderately 
sensitive 
substrate 
Inhibition of CYP3A4 mediated 
phenytoin metabolism Moderate 
Results in increase plasma 
concentration of phenytoin 
and phenytoin toxicity. 
Phenytoin dose should be reduced. 
Domperidone Amlodipine 2 3.03 - - Inhibition of CYP3A4 mediated domperidone metabolism Major 
Results in increased 
domperidone concentration 
in plasma 
Domperidone should be given at 
lowest possible dose. 
Domperidone Atorvastatin 2 3.03 - - Inhibition of CYP3A4 mediated domperidone metabolism Major 
Results in increased 
domperidone concentration 
in plasma 
Domperidone should be given at 
lowest possible dose. 
Clopidogrel Isoniazid 2 3.03 - - 
Inhibition of CYP2C19 and 
CYP3A4 mediated clopidogrel 
metabolism to active metabolite 
by isoniazid 
Moderate 
Results in reduced 
antiplatelet activity of 
clopidogrel 
Avoid concomitant use of both 
these drugs. 
Azithromycin Atorvastatin 2 3.03 Strong inhibitor 
Sensitive 
substrate 
Inhibition of CYP3A4 mediated 
azithromycin metabolism Moderate 
Concurrent use may lead to 
rhabdomylosis 
Avoid concomitant use and check 
for rhabdomylosis. Rosuvastatin 
can be preferred choice of statins 
for a concomitant therapy with 
azithromycin. 
Clopidogrel Omeprazole 1 1.51 Moderate inhibitor 
Moderately 
sensitive 
substrate 
Inhibition of CYP2C19 and 
CYP3A4mediated clopidogrel 
metabolism by omeprazole 
Major 
Results in reduction in 
clinical efficacy of 
clopidogrel and increase in 
risk for thrombosis 
Use dexlanzoprazole instead of 
omeprazole for concomitant 
therapy with clopidogrel. 
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Table 8: Substrates and Inducers of CYP3A4 mediated metabolism (n=34) 
Substrate Precipitant No. % 
Strength 
of 
Inhibition 
Strength of 
Substrate 
Mechanism 
of Interaction 
Severity of 
Interaction 
Effect of 
Interaction 
Pharmacist 
Recommendation 
Atorvastatin Phenytoin 12 35.29 Moderate inhibitor 
Moderately 
sensitive 
substrate 
Induction of 
CYP3A4 
mediated 
atorvastatin 
metabolism 
by phenytoin 
Moderate 
Results in 
decreased 
atorvastatin 
plasma 
concentration 
and 
decreased 
atorvastatin 
efficacy 
Adjust the dose of 
atorvastatin. 
Rosuvastatin can be 
replaced instead of 
atorvastatin. 
Esomeprazole Rifampicin 9 26.47 Moderate inhibitor 
Moderately 
sensitive 
substrate 
Induction of 
CYP3A4 and 
CYP2C19 
mediated 
esomeprazole 
metabolism 
by rifampicin 
Moderate 
Concurrent 
use may 
result in 
decreased 
esomeprazole 
plasma 
concentration 
Avoid concurrent 
use of these drugs. 
Atorvastatin Rifampicin 5 14.70 Strong inhibitor 
Sensitive 
substrate 
Induction of 
CYP3A4 Severe 
Concurrent 
use may 
Atorvastatin 
administration 
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Substrate Precipitant No. % 
Strength 
of 
Inhibition 
Strength of 
Substrate 
Mechanism 
of Interaction 
Severity of 
Interaction 
Effect of 
Interaction 
Pharmacist 
Recommendation 
metabolism 
of 
atorvastatin 
by rifampicin 
result in 
decreased 
plasma 
concentration 
of 
atorvastatin 
should be delayed 
after rifampicin 
administration 
Omeprazole Rifampicin 5 14.70 Moderate inhibitor 
Moderately 
sensitive 
substrate 
Induction of 
CYP3A4 and 
CYP2C19 
mediated 
omeprazole 
metabolism 
by rifampicin 
Moderate 
Concurrent 
use may 
result in 
decreased 
omeprazole 
plasma 
concentration 
Avoid concurrent 
use of these drugs. 
Results  
 
 
 
 
Inducers and Inhibitors of Cytochrome P450 3A4 Substrates  
and the Management of  their Drug Interactions        44 
 
Substrate Precipitant No. % 
Strength 
of 
Inhibition 
Strength of 
Substrate 
Mechanism 
of Interaction 
Severity of 
Interaction 
Effect of 
Interaction 
Pharmacist 
Recommendation 
Midazolam Phenytoin 3 8.82 - - 
Induction of 
CYP3A4 
mediated 
midazolam 
metabolism 
by phenytoin 
Moderate 
Results in 
decreased 
midazolam 
plasma 
concentration 
and reduction 
in midazolam 
efficacy. 
A hypnotic other 
than midazolam 
would be preferable. 
Benzodiazepines 
(Diazepam) 
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DISCUSSION 
 Hundred drug-drug interaction based on CYP3A4 metabolism of drugs 
were obtained from the current study. Of these 66 were between CYP3A4 
substrates and inhibitors while 34 were between CYP3A4 substrates and inducers. 
 Most prevalent interacting combination of CYP3A4 substrate and inhibitor 
was clopidogrel + atorvastatin (39.39%) followed by clopidogrel + amlodipine 
(16.66%). Most frequently observed interacting combination of CYP3A4 substrate 
with an inducer was atorvastatin + phenytoin (35.29%) followed by esomeprazole 
+ rifampicin (26.47%). 
 The clinical significane of each interacting drug combination along with 
pharmacist’s recommendation for a suitable therapeutic alternative are discussed 
below. 
1. CLOPIDOGREL  +  ATORVASTATIN 
 CYP3A4 based interaction between clopidogrel and atorvastsatin leads to 
decreased formation of clopidogrel active metabolite in plasma resulting in high 
platelet activity leading to thrombosis. This is due to the competition with 
CYP3A4 mediated metabolism of clopidogrel by atorvastatin and inhibition of P-
glycoprotien efflux transport of clopidogrel. In presence of pravastatin and 
rosuvastatin the clearance of clopidogrel reduces to 24% and 46% respectively. 
Hence instead of atorvastatin either pravastatin or rosuvastatin may be prescribed 
in combination with clopidogrel14. 
2. ESOMEPRAZOLE  +  FLUCANAZOLE 
 Due the inhibition of CYP2C19 and CYP3A4 mediated esomeprazole 
metabolism, esomeprazole exposure may increase by more than two fold when 
administered concurrently with flucanazole. However, flucanazole is a moderately 
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sensitive substrate of CYP3A4 based metabolism of esomeprazole. Patients 
should be monitored for potentially increased adverse effects of PPIs during co-
administration32.  
3. PHENYTOIN + OXCARBAZEPINE  
 When phenytoin was combined with oxcarbazepine in dose greater than 
1200 to 2400 mg daily, there was upto a 40% increase in phenytoin plasma 
concentrations. But oxcarbazepine in a moderate inhibitor of CYP3A4 mediated 
metabolism of phenytoin. Therefore dose reduction of phenytoin may be 
considered33.   
4. AZITHROMYCIN + ATORVASTATIN 
 Bellosta et al 2012 have reported 73% decrease in the clearance of 
azithromycin when coadministered with atorvastatin due to inhibition of CYP3A4 
metabolism of azithromycin by atorvastatin. Cytochrome P450 metabolism of 
rosuvastatin appears to be minimal (10%) and is principally mediated by CYP2C9 
enzyme with little involvement of 3A4. Literature also supports the absence of 
clinically significant pharmacokinetic drug-drug interaction between rosuvastatin 
and other CYP substrates. Therefore, rosuvastatin can be a preferred choice of 
statin for concomitant therapy with azithromycin16. 
5. CLOPIDOGREL + OMEPRAZOLE 
 In dedicated drug-drug interaction studies, proton pump inhibitors 
(dexlansoprazole, lansoprazole, pantoprazole, rabeprazole and omeprazole) use 
significantly reduced the AUC of the clopidogrel active metabolite versus 
clopidogrel alone. Omeprazole use resulted in the greatest reduction in clopidogrel 
metabolite AUC, while  dexlansoprazole was associated with the least reduction. 
Therefore when such a combition therapy is necessary omeprazole may be 
replaced with dexlansoprazole34.  
6. ATORVASTATIN + PHENYTOIN 
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 Phenytoin induces CYP3A4 mediated metabolism of atorvastatin, resulting 
in decreased atorvastatin plasma concentration and decreased atorvastatin 
efficacy. When such a combination therapy is necessary, the dose of atorvastatin 
may be adjusted. However, rosuvastatin, which is minimally metabolized (10%) 
by CYP enzyme system, can be recommended instead of atorvastatin. Also, there 
is no documented evidence of interaction between rosuvastatin and phenytoin35.  
 
7. ATORVASTATIN + RIFAMPICIN 
 Eighty percentage decrease in AUC and 40% decrease in Cmax of 
atorvastatin when given along with rifampcin was reported by Backman et al 
2005. Mechanism of this interaction is induction of CYP3A4 metabolism of 
atorvastatin by rifampicin. Hence atorvastatin administration should be delayed 
after rifampicin administration30.  
 
8. ESOMEPRAZOLE + RIFAMICIN 
 Esomeprazole Cmax and AUC decreased by 37.5% and 37.9%, 
respectively in poor metabolizers, and by 49.6% and 43.9%, respectively in 
extensive metabolizers (Willington et al 2011) Rifampcin induces CYP3A4 and 
CYP2C19 mediated metabolism of omeprazole. Hence concurrent therapy may be 
avoided32.  
 
9. OMEPRAZOLE +  RIFAMPICIN 
 Omeprazole rifampicin coadministratin also yielded results similar to 
previous studies32.  
 
Summary 
 
 
 
Inducers and Inhibitors of Cytochrome P450 3A4 Substrates  
and the Management of  their Drug Interactions  48 
SUMMARY 
 A prospective observational study for a period of 8 months was carried out 
in the general medicine department of a 750 bedded multispecialty tertiary care 
teaching hospital in order to understand various inducers and inhibitors of 
CYP3A4 substrates present in prescription and to follow a mechanism based 
approach in the management of drug-drug interactions.  Hundred Prescriptions 
with at least one CYP3A4 enzyme substrate along with either inducer or inhibitor 
were selected for the study. All the selected prescriptions had at least one 
CYP3A4 enzyme substrate along with an inducer or inhibitor. Major diagnosis 
observed in study population were hypertension (21%) followed by diabetes 
mellitus (14%), chronic renal failure (12%), and tuberculosis (9%) Nine hundred 
and twenty five drugs belonging to Eighty eight categories were prescribed in the 
study subjects. Of these, vitamins and minerals (33.63%), antibiotics (12.5%), 
antihypertensives (9.09%), antiulcers (6.81%), antiepileptic (6.81%) and 
anticoagulants (6.81%) were most frequently prescribed. Hundred substrates, 66 
inhibitors and 34 inducers of CYP3A4 were identified during the study period. 
The substrates included clopidogrel (47%), atorvastatin (22%), esomeprazole 
(13%),omeprazole (5%) domperidone (4%), midazolam (3%), phenytoin (2%) and 
azithromycin (2%). The various inhibitors of CYP3A4 recorded were atorvastatin 
(45.45%),  amlodipine (19.69%), esomeprazole (12.12%), amiodarone (7.57%), 
flucanazole (6.06%), cloidogrel (3.03%), oxcarbamazeine(3.03%) and isoniazid 
(3.03%). Inducers of CYP3A4 enzyme present in the prescritions were phenytoin 
(55.88%) and rifampicin (44.11%). The study reviewed the strength of 
inhibition/induction of metabolism of the CY3A4 substrate by the 
inhibitors/inducers. Mechanism of these interactions as well as the severity and 
clinical significance of interactions were also reviewed using relevant literatures. 
A suitable therapeutic alternative was recommended whenever possibility of a 
major drug-drug interaction between CY3A4 substrate and inhibitor/inducer was 
observed in the study.    
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CONCLUSION 
 Evaluation of 100 prescriptions in the current study resulted 66 drug-drug 
interactions between CYP3A4 substrates with inhibitors and 34 between CYP3A4 
substrates and inducers. The most commonly identified combination was 
clopidogrel+atorvastatin (39.39%) and clopidogrel+amlodipine (16.66%). Both 
atorvastatin and amlodipine act as an inhibitor of CYP3A4 based metabolism of 
clopidogrel, possibly resulting in decreased formation of copidogrel active 
metabolite in plasma. Rosuvastatin which is minimally metabolized by CYP 
enzyme system may be substituted instead of atorvastatin. The study also 
identified phenytoin (35.92%) and rifampicin (26.47%) as the inducers of 
CYP3A4 based metabolism of atorvastatin and esomeprazole leading to a 
decreased plasma concentration of atorvastatin and esomeprazole.  
Future  Outlook 
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FUTURE OUTLOOK 
 Further studies are needed to assess the impact of pharmacist 
recommendation on reducing major drug-drug interaction of CYP3A4 substrates 
with inhibitors or inducers. The present study may also be extended to other 
departments of the hospital. 
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